EIF2AK3 and liver disorder: Therapies designed to inhibit ER stress by interfering with its associated signaling, such as broad-spectrum ER stress-reducing agents (4-PBA or TUDCA) and targeting canonical UPR branches (PERK or IRE inhibitors), have been tested as potential treatments for liver diseases [106,107].